Sign in Subscribe
Brachytherapy

Prostate Cancer Research Finds No Difference Between High-Dose and Low-Dose Radiation Therapy

Strategic Insights

— 1 min read

New research from a trial in Kelowna, Canada, has found that patients with unfavorable localized prostate cancer treated with combined pelvic external beam radiation therapy and prostate brachytherapy have similar efficacy outcomes at 5 and 8 years with either high-dose rate (HDR) or low-dose rate (LDR) brachytherapy. The study, published in the International Journal of Radiation Oncology*Biology*Physics, compared the outcomes of 195 men randomly assigned to either HDR or LDR brachytherapy and found no significant difference in biochemical failure-free survival (bPFS) at 5 and 8 years. The study also confirmed the excellent efficacy of dose escalation using prostate brachytherapy for unfavorable localized prostate cancer.

Key Takeaways:

  • The study compared the efficacy of high-dose rate (HDR) and low-dose rate (LDR) brachytherapy combined with external beam radiation therapy for patients with unfavorable localized prostate cancer.
  • The study included 195 men randomly assigned to either HDR (108 patients) or LDR (87 patients) brachytherapy.
  • The median age of the patients was 71 years, and the median prostate-specific antigen (PSA) level was 11.6 ng/mL.
  • The median follow-up was 74 months, and the study found no significant difference in biochemical failure-free survival (bPFS) at 5 and 8 years between the HDR and LDR groups.
  • The study confirmed the excellent efficacy of dose escalation using prostate brachytherapy for unfavorable localized prostate cancer.
  • The study suggested that either HDR or LDR brachytherapy can be used as a boost to external beam radiation therapy for patients with unfavorable localized prostate cancer.

Statistics:

  • The study included 195 men with unfavorable localized prostate cancer.
  • Median age: 71 years.
  • Median PSA: 11.6 ng/mL.
  • Median follow-up: 74 months.
  • Biochemical failure-free survival (bPFS) at 5 years: 86% (HDR) and 85% (LDR).
  • Biochemical failure-free survival (bPFS) at 8 years: 86% (HDR) and 85% (LDR).
  • Eighteen of 22 biochemical failures have been identified; 3 are isolated local failures, whereas 14 are distant failures.

Sources:

  • A Randomized Comparison of High-Dose-Rate and Low-Dose-Rate Prostate Brachytherapy Combined With External Beam Radiation Therapy for Unfavorable Prostate Cancer: Efficacy Results After Median Follow-up of 74 Months. International Journal of Radiation Oncology*Biology*Physics, 2025.
  • NewsRx. Data on Prostate Cancer Reported by Juanita Crook and Colleagues (A Randomized Comparison of High-Dose-Rate and Low-Dose-Rate Prostate Brachytherapy Combined With External Beam Radiation Therapy for Unfavorable Prostate Cancer: Efficacy Results ...). Chemicals & Chemistry. May 23, 2025; p 629.

Read more